
Dominic Atkins joins Clinigen GAP in senior commercial role
pharmafile | January 14, 2013 | Appointment | Manufacturing and Production, Research and Development, Sales and Marketing | Clinigen, Dominic Atkins
Pharma services company Clinigen Global Access Programs (Clinigen GAP) has appointed Dominic Atkins as global business development director.
In this senior commercial role reporting to Mark Corbett, Clinigen GAP’s vice-president, Atkins will be responsible for identifying, assessing and developing new international business opportunities across the pharmaceutical product lifecycle. He will be based near Basel in Switzerland.
In a career spanning almost 20 years, Atkins has developed expertise in sales and marketing at national and international level. He also has experience in public policy/issues management, alliance management and business development.
Recently Atkins held a senior marketing position at Shire Human Genetics Therapies (Shire HGT), where he led and implemented marketing strategies throughout the EMEA region.
Corbett said: “We are delighted that Dominic has decided to join Clinigen GAP at such an exciting stage of our development. We are enjoying strong growth in our business and he is an excellent addition to our team. Dominic brings tremendous knowledge of the industry, as well as insights into our key strategic areas of speciality pharma and orphan drugs.”
Related Content

Clinigen becomes sole license holder of cancer drug Proleukin in $210m deal
Novartis has arranged to sell the remainder of its rights to its skin and lung …

Clinigen shares soar after $210m Novartis cancer drug deal
British company Clinigen has bought the rights to sell Novartis’ cancer drug Proleukin in the …

Eisai & Clinigen to bring breast cancer drug to South Africa
Eisai and Clinigen have formed a collaboration to deliver the former’s cancer treatment Halaven (eribulin) …






